Coronary Artery Disease Screening in Patients With Chronic Kidney Disease

NCT07585695 | Not Yet Recruiting

• 2 other identifiers: 38RC25.0302IDRCB 2025-A02537-42
• Study Type: observational
• Target: 283
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.

Conditions

Chronic Kidney Disease (CKD); Coronary Artery Disease (CAD)

Keywords

Chronic Kidney Disease; Coronary Flow Reserve; coronary artery disease

Outcome Measures

Primary Outcomes (1)

• To assess the prognostic value of impaired coronary flow reserve measured by CZT myocardial perfusion imaging

  Composite endpoint including cardiac mortality, non-fatal myocardial infarction, non-fatal ischemic stroke, and hospitalization for heart failure.

  2-year follow-up

Secondary Outcomes (5)

• To assess the prognostic value of coronary flow reserve to each individual component of the primary endpoint

  2 years

• To assess the prognostic value of coronary flow reserve for Major Adverse Kidney Events (MAKE)

  At 1-year and 2-year follow-up

• To assess the number of Acute Kidney Injury (AKI) events during follow-up

  2 years

• To assess the number of coronary revascularizations by coronary artery bypass grafting or percutaneous coronary intervention

  2 years

• To assess the prevalence of ischemic heart disease without significant coronary artery stenosis (INOCA)

  2 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients from the University Hospital of Grenoble

You may qualify if:

• Male or female patients aged over 18 years
• Affiliated with the French social security system
• Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR \< 30 mL/min/1.73 m², or GFR \< 45 mL/min/1.73 m² with albuminuria \> 30 mg/g, or GFR \< 60 mL/min/1.73 m² with albuminuria \> 300 mg/g)
• Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment
• Having expressed no objection to participation in this study

You may not qualify if:

• Legally protected adult (Article L1121-8 of the French Public Health Code)
• Person deprived of liberty (Article L1121-8 of the French Public Health Code)
• Pregnant woman
• Patient who has undergone a normal coronary exploration within the past year

Sponsors & Collaborators

• University Hospital, Grenoble: lead

Study Sites (1)

CHU Grenoble Alpes

La Tronche, France, 38700, France

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Coronary Artery Disease

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Central Study Contacts

Gilles Barone Rochette

CONTACT

+33476765172; gbarone@chu-grenoble.fr

Clémence Charlon

CONTACT

+33476766652; ccharlon@chu-grenoble.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 25 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 6, 2026
• First Posted: May 14, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): November 30, 2027
• Study Completion (Estimated): January 31, 2028
• Last Updated: May 14, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)